4564.T
OncoTherapy Science,Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 22.00
+4.76%Year over year
Reported trailing growth
- Revenue
- +10.9%
- EBITDA
- —
- EBIT
- +6.3%
- EPS
- +29.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -13.4%
- EBITDA
- —
- EBIT
- +28.8%
- Net income
- +36.7%
- EPS
- +48.4%
- Free cash flow
- +33.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026